Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro

被引：133

作者：

Delaney, WE

Edwards, R

Colledge, D

Shaw, T

Furman, P

Painter, G

Locarnini, S

机构：

[1] Victorian Infect Dis Reference Lab, Melbourne, Vic 3051, Australia

[2] Triangle Pharmaceut, Durham, NC 27707 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2002年 / 46卷 / 09期

关键词：

D O I：

10.1128/AAC.46.9.3057-3060.2002

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The phenylpropenamide derivatives AT-61 and AT-130 are nonnucleoside analogue inhibitors of hepatitis B virus (HBV) replication. They inhibited the replication of wild-type HBV with 50% inhibitory concentrations of 21.2 +/- 9.5 and 2.40 +/- 0.92 muM, respectively, compared to 0.064 +/- 0.020 muM lamivudine. There were no significant differences in sensitivity between wild-type and nucleoside analogue-resistant (rtL180M, rtM204I, and rtL180M + rtM204V) HBV.

引用

收藏

页码：3057 / 3060

页数：4

相关论文

共 34 条

[1] Identification and characterization of mutations in hepatitis B virus resistant to lamivudine [J].

Allen, MI ;

Deslauriers, M ;

Andrews, CW ;

Tipples, GA ;

Walters, KA ;

Tyrrell, DLJ ;

Brown, N ;

Condreay, LD .

HEPATOLOGY, 1998, 27 (06) :1670-1677

[2] Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation [J].

Aye, TT ;

Bartholomeusz, A ;

Shaw, T ;

Bowden, S ;

Breschkin, A ;

McMillan, J ;

Angus, P ;

Locarnini, S .

JOURNAL OF HEPATOLOGY, 1997, 26 (05) :1148-1153

[3] Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation [J].

Bartholomew, MM ;

Jansen, RW ;

Jeffers, LJ ;

Reddy, KR ;

Johnson, LC ;

Bunzendahl, H ;

Condreay, LD ;

Tzakis, AG ;

Schiff, ER ;

Brown, NA .

LANCET, 1997, 349 (9044) :20-22

[4]

Colacino JM, 1998, PROG DRUG RES, V50, P259

[5] In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir [J].

Colledge, D ;

Civitico, G ;

Locarnini, S ;

Shaw, T .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (03) :551-560

[6] A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B [J].

de Man, RA ;

Marcellin, P ;

Habal, F ;

Desmond, P ;

Wright, T ;

Rose, T ;

Jurewicz, R ;

Young, C .

HEPATOLOGY, 2000, 32 (02) :413-417

[7]

Delaney WE, 2001, ANTIVIR CHEM CHEMOTH, V12, P1

[8] Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus [J].

Delaney, WE ;

Edwards, R ;

Colledge, D ;

Shaw, T ;

Torresi, J ;

Miller, TG ;

Isom, HC ;

Bock, CT ;

Manns, MP ;

Trautwein, C ;

Locarnini, S .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1705-1713

[9] Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant Baculovirus [J].

Delaney, WE ;

Isom, HC .

HEPATOLOGY, 1998, 28 (04) :1134-1146

[10] Lamivudine as initial treatment for chronic hepatitis B in the United States [J].

Dienstag, JL ;

Schiff, ER ;

Wright, TL ;

Perrillo, RP ;

Hann, HWL ;

Goodman, Z ;

Crowther, L ;

Condreay, LD ;

Woessner, M ;

Rubin, M ;

Brown, NA .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (17) :1256-1263

← 1 2 3 4 →